Mass General: Phase 3 Clinical Trial Results Lead to Approval of Oral Drug for Red Blood Cell Disorder
April 16, 2022
April 16, 2022
BOSTON, Massachusetts, April 16 (TNSJou) -- Massachusetts General Hospital issued the following news release:
Researchers have published the results of a clinical trial that led the U.S. Food and Drug Administration to recently approve mitapivat for the treatment of adults with pyruvate kinase deficiency-a rare genetic condition that leads to the destruction of red blood cells, or hemolytic anemia. The primary results from the global, phase 3, randomized, placebo-controlled ACTIVATE . . .
Researchers have published the results of a clinical trial that led the U.S. Food and Drug Administration to recently approve mitapivat for the treatment of adults with pyruvate kinase deficiency-a rare genetic condition that leads to the destruction of red blood cells, or hemolytic anemia. The primary results from the global, phase 3, randomized, placebo-controlled ACTIVATE . . .